TW202304458A - 用於黑色素瘤之組合治療 - Google Patents

用於黑色素瘤之組合治療 Download PDF

Info

Publication number
TW202304458A
TW202304458A TW111111247A TW111111247A TW202304458A TW 202304458 A TW202304458 A TW 202304458A TW 111111247 A TW111111247 A TW 111111247A TW 111111247 A TW111111247 A TW 111111247A TW 202304458 A TW202304458 A TW 202304458A
Authority
TW
Taiwan
Prior art keywords
combination
inhibitor
melanoma
months
azd6738
Prior art date
Application number
TW111111247A
Other languages
English (en)
Chinese (zh)
Inventor
西蒙 安卓 史密斯
艾瑪 珍 狄恩
李知胤
Original Assignee
瑞典商阿斯特捷利康公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 瑞典商阿斯特捷利康公司 filed Critical 瑞典商阿斯特捷利康公司
Publication of TW202304458A publication Critical patent/TW202304458A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
TW111111247A 2021-03-26 2022-03-25 用於黑色素瘤之組合治療 TW202304458A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163166295P 2021-03-26 2021-03-26
US63/166,295 2021-03-26
US202163208728P 2021-06-09 2021-06-09
US63/208,728 2021-06-09

Publications (1)

Publication Number Publication Date
TW202304458A true TW202304458A (zh) 2023-02-01

Family

ID=81449142

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111111247A TW202304458A (zh) 2021-03-26 2022-03-25 用於黑色素瘤之組合治療

Country Status (11)

Country Link
US (1) US20240197748A1 (https=)
EP (1) EP4313057A1 (https=)
JP (1) JP2024512558A (https=)
KR (1) KR20230162030A (https=)
AU (2) AU2022245277B8 (https=)
BR (1) BR112023019433A2 (https=)
CA (1) CA3213407A1 (https=)
IL (1) IL306028A (https=)
MX (1) MX2023011332A (https=)
TW (1) TW202304458A (https=)
WO (1) WO2022200557A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL297842A (en) * 2020-05-11 2023-01-01 Astrazeneca Ab ATR inhibitors for cancer treatment
WO2025233224A1 (en) * 2024-05-09 2025-11-13 F. Hoffmann-La Roche Ag Use of atr inhibitors in combination with anti-pd(l)1 therapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
PL2504364T3 (pl) 2009-11-24 2017-12-29 Medimmune Limited Ukierunkowane środki wiążące przeciwko B7-H1
SA111320519B1 (ar) 2010-06-11 2014-07-02 Astrazeneca Ab مركبات بيريميدينيل للاستخدام كمثبطات atr
WO2015036499A1 (en) * 2013-09-11 2015-03-19 Medimmune Limited Anti-b7-h1 antibodies for treating tumors
IL297842A (en) * 2020-05-11 2023-01-01 Astrazeneca Ab ATR inhibitors for cancer treatment

Also Published As

Publication number Publication date
IL306028A (en) 2023-11-01
WO2022200557A1 (en) 2022-09-29
KR20230162030A (ko) 2023-11-28
CA3213407A1 (en) 2022-09-29
AU2025252564A1 (en) 2025-11-27
MX2023011332A (es) 2023-10-03
JP2024512558A (ja) 2024-03-19
US20240197748A1 (en) 2024-06-20
EP4313057A1 (en) 2024-02-07
AU2022245277A9 (en) 2023-11-16
AU2022245277B1 (en) 2025-07-17
AU2022245277A1 (en) 2023-11-02
BR112023019433A2 (pt) 2023-10-24
AU2022245277B8 (en) 2025-08-07

Similar Documents

Publication Publication Date Title
CN115515577A (zh) 用于治疗癌症的atr抑制剂
ES3055227T3 (en) Method of treating cancer using immune checkpoint inhibitor; antibody that binds to programmed death-1 receptor (pd-1) or programmed death ligand 1 (pd-l1)
JP6695003B2 (ja) 癌のための併用療法
AU2025252564A1 (en) Combination treatments for melanoma
JP2024028805A (ja) がん処置のための坑ｉｌ－８抗体及び坑ｐｄ－１抗体を用いる組合せ治療
JP2019503387A (ja) 抗ｐｄ−１抗体および別の抗癌剤の組合せを用いる肺癌の処置法
JP2019510785A (ja) 癌を処置する方法
CN115443152A (zh) 使用pd-1拮抗剂、ctla4拮抗剂以及仑伐替尼或其药学上可接受的盐的组合治疗癌症的方法
KR102760684B1 (ko) 암을 치료하기 위한 조성물 및 방법
TW202535399A (zh) 用於治療實性瘤之方法與包含 krasg12c 抑制劑及 vegf 抑制劑之組成物
CN119997973A (zh) 使用间充质上皮转化因子（met）靶向剂治疗非小细胞肺癌的方法
EA052375B1 (ru) Варианты комбинированного лечения меланомы
CN117098539A (zh) 用于黑色素瘤的组合治疗
WO2025212469A1 (en) Use of an immunoconjugate for the treatment of gastric cancer
CN120957724A (zh) 索托拉西布/卡铂/培美曲塞在癌症治疗中的剂量方案
CN114432438A (zh) 喹啉衍生物与pd-1单抗的药物组合
Smyth et al. Clinical Trial Registration: The trial is registered with www. ClinicalTrials. gov, identifier: NCT03443856.